...NEOP began selling the Neoprobe 1500 Portable Radioisotope Detector, a hand-held device that detects gamma rays...
...radiopharmaceutical. NEOP will sell the product through its 14-member sales team. Average price is $34,000. Neoprobe Corp....

...patent. The peptides are in various stages of testing to surgically detect and treat cancer. Neoprobe Corp....

...which combines cancer-specific targeting agents. The product is designed to find hidden tumors during surgery. Neoprobe Corp....

...amyloid imaging agents - AZD2184 and AZD2995 - to a 2011 deal granting Navidea (formerly Neoprobe Corp....

...extended the PDUFA date by 90 days for diagnostic product Lymphoseek tilmanocept from Navidea (formerly Neoprobe Corp....

...mapping. The new date is Sept. 10; it was June 10. According to Navidea (formerly Neoprobe Corp....

...Capital Note: The 30-month secured note bears interest at a prime-based variable rate. Navidea (formerly Neoprobe Corp....

...AstraZeneca granted Neoprobe exclusive, worldwide rights to AZD4694 , a late-stage radiopharmaceutical imaging agent that binds...
...in clinical and regulatory submission milestones and an additional $11 million upon approval, plus royalties. Neoprobe...
...AstraZeneca retains rights to use AZD4694 in clinical trials to support development of AD treatments. Neoprobe Corp....

...BF-200 ALA ) to treat actinic keratosis. Biofrontera gained €0.66 (20%) for the week. Neoprobe Corp....